Reuters -- Icagen Inc said U.S. health regulators lifted the partial clinical hold from its experimental epilepsy drug. In March, the U.S. Food and Drug Administration decided to put Icagen’s epilepsy drug, ICA-105665, on a partial clinical hold, based on certain pre-clinical data.
